WO1997046697A3 - Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections - Google Patents

Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections Download PDF

Info

Publication number
WO1997046697A3
WO1997046697A3 PCT/US1997/009449 US9709449W WO9746697A3 WO 1997046697 A3 WO1997046697 A3 WO 1997046697A3 US 9709449 W US9709449 W US 9709449W WO 9746697 A3 WO9746697 A3 WO 9746697A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
hiv
immunodeficiency virus
directed
primary isolates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/009449
Other languages
French (fr)
Other versions
WO1997046697A2 (en
Inventor
Chang Yi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/808,374 external-priority patent/US5961976A/en
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Priority to JP10500752A priority Critical patent/JP2000511775A/en
Priority to AU31529/97A priority patent/AU3152997A/en
Priority to BRPI9709524A priority patent/BRPI9709524B8/en
Priority to DE69736474T priority patent/DE69736474T2/en
Priority to CA2256306A priority patent/CA2256306C/en
Priority to EP97926870A priority patent/EP0910659B1/en
Publication of WO1997046697A2 publication Critical patent/WO1997046697A2/en
Publication of WO1997046697A3 publication Critical patent/WO1997046697A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention is directed to monoclonal antibodies produced by using CD4-expressing T lymphocytes, such as peripheral blood mononuclear T cells, thymocytes, splenocytes and leukemia or lymphoma derived T cell line cells such as HPB-ALL or SUP-T as the immunogen in accordance with the protocols and screening procedures described. The monoclonal antibodies of the present invention are characterized by their ability to neutralize in vitro and in vivo primary isolates of Human Immunodeficiency Virus (HIV) and related immunodeficiency viruses. The antibodies are directed against a host cell antigen complex comprising CD4 protein in association with domains from chemokine receptors and have broad neutralizing activities against primary isolates from all clades of HIV type 1 (HIV-1) and primary isolates of HIV type 2 (HIV-2) and Simian Immunodeficiency Virus (SIV). The present invention is also directed to a method of selecting and producing such antibodies, hybridomas which secrete such antibodies, pharmaceutical compositions comprising such antibodies and methods for pre- and post-exposure prevention of immunodeficiency virus infection in primates, including humans, by such antibodies whose primary targets are CD4-expressing lymphocytes.
PCT/US1997/009449 1996-06-03 1997-06-03 Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections Ceased WO1997046697A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP10500752A JP2000511775A (en) 1996-06-03 1997-06-03 Antibodies to the complex of CD4 and chemokine receptor regions and their use against HIV infection
AU31529/97A AU3152997A (en) 1996-06-03 1997-06-03 Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
BRPI9709524A BRPI9709524B8 (en) 1996-06-03 1997-06-03 process for producing an antibody to cd4 expressing t cells
DE69736474T DE69736474T2 (en) 1996-06-03 1997-06-03 ANTIBODIES AGAINST A COMPLEX OF CD4 AND A CHEMOKIN RECORD CORDOMA, AND THEIR USE AGAINST HIV INFECTIONS
CA2256306A CA2256306C (en) 1996-06-03 1997-06-03 Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
EP97926870A EP0910659B1 (en) 1996-06-03 1997-06-03 Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US65714996A 1996-06-03 1996-06-03
US08/657,149 1996-06-03
US08/808,374 US5961976A (en) 1996-06-03 1997-02-28 Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US08/808,374 1997-02-28
US08/867,149 US5912176A (en) 1996-06-03 1997-06-02 Antibodies against a host cell antigen complex for pre and post exposure protection from infection by HIV
US08/867,149 1997-06-02

Publications (2)

Publication Number Publication Date
WO1997046697A2 WO1997046697A2 (en) 1997-12-11
WO1997046697A3 true WO1997046697A3 (en) 1997-12-11

Family

ID=27417977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/009449 Ceased WO1997046697A2 (en) 1996-06-03 1997-06-03 Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections

Country Status (10)

Country Link
EP (1) EP0910659B1 (en)
JP (1) JP2000511775A (en)
CN (1) CN1227610A (en)
AT (1) ATE335835T1 (en)
BR (1) BRPI9709524B8 (en)
CA (1) CA2256306C (en)
DE (1) DE69736474T2 (en)
DK (1) DK0910659T3 (en)
ES (1) ES2270461T3 (en)
WO (1) WO1997046697A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504755B2 (en) 2008-08-11 2016-11-29 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AU2722600A (en) * 1999-01-08 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Inhibition of cd4-ccr5 interaction
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CL2008000707A1 (en) 2007-03-13 2008-09-22 Hoffmann La Roche CONJUGATE OF ANTIFUSOGENIC POLYPEPTIDES AND POLYPEPTIDES DERIVED FROM THE GLOBULAR HEAD OF THE COMPLEMENT FACTOR C1Q; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; ITS USE TO TREAT VIRIC INFECTIONS; AND PRODUCTION METHOD.
AR067584A1 (en) 2007-07-20 2009-10-14 Hoffmann La Roche A CONJUGATE OF AN ANTIBODY AGAINST CD4 AND ANTIFUSOGENIC PEPTIDES
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN102649818B (en) * 2011-02-25 2014-10-08 厦门大学 CD4 protein-resistant monoclonal antibody and active fragment and application thereof
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
HRP20200583T1 (en) 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0409242A1 (en) * 1989-07-21 1991-01-23 The Calpis Food Industry Co., Ltd. Monoclonal antibody against human CD4 peptide
WO1994015638A1 (en) * 1992-12-31 1994-07-21 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
WO1996041884A1 (en) * 1995-06-09 1996-12-27 Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom) Means for detecting and preventing hiv infection involving use of receptors or binding sites capable of interacting with gp120

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0915969A4 (en) * 1996-04-02 2002-04-17 Progenics Pharm Inc Method for preventing hiv-1 infection of cd4+ cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0409242A1 (en) * 1989-07-21 1991-01-23 The Calpis Food Industry Co., Ltd. Monoclonal antibody against human CD4 peptide
WO1994015638A1 (en) * 1992-12-31 1994-07-21 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
WO1996041884A1 (en) * 1995-06-09 1996-12-27 Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom) Means for detecting and preventing hiv infection involving use of receptors or binding sites capable of interacting with gp120

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. TRKOLA ET AL.: "CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.", NATURE, vol. 384, no. 6605, 14 November 1996 (1996-11-14), LONDON, GB, pages 184 - 187, XP002056371 *
H. DENG ET AL.: "Identification of a major co-receptor for primary isolates of HIV-1.", NATURE, vol. 381, no. 6584, 20 June 1996 (1996-06-20), LONDON, GB, pages 661 - 666, XP002056370 *
M. SAMSON ET AL.: "Molecular cloning and functional expression of a new human CC-chemokine receptor gene.", BIOCHEMISTRY, vol. 35, no. 11, 19 March 1996 (1996-03-19), USA, pages 3362 - 3367, XP002056369 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504755B2 (en) 2008-08-11 2016-11-29 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates

Also Published As

Publication number Publication date
EP0910659B1 (en) 2006-08-09
ES2270461T3 (en) 2007-04-01
DE69736474D1 (en) 2006-09-21
CA2256306A1 (en) 1997-12-11
CN1227610A (en) 1999-09-01
DE69736474T2 (en) 2007-01-18
DK0910659T3 (en) 2006-11-27
ATE335835T1 (en) 2006-09-15
WO1997046697A2 (en) 1997-12-11
EP0910659A2 (en) 1999-04-28
BRPI9709524B8 (en) 2021-05-25
JP2000511775A (en) 2000-09-12
CA2256306C (en) 2011-03-29
BR9709524A (en) 2000-05-09
BRPI9709524B1 (en) 2016-11-01

Similar Documents

Publication Publication Date Title
DK0910659T3 (en) Antibodies to a complex of CD4 and a chemokine receptor domain and their use against HIV infections
Bures et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa
Ferrari et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum
Bastiani et al. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions
Lyerly et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC
JP2755395B2 (en) Antibody heteroconjugate that kills HIV-infected cells
DK0479909T3 (en) Bispecific reagents for AIDS treatment
Amadori et al. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients
EP0675904A4 (en) HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS.
ATE405679T1 (en) SYNTHETIC HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST HIV
ATE122237T1 (en) HIV-1 NEUTRALIZING MONOCLONAL ANTIBODIES.
CA2170034A1 (en) Recombinant humanized anti-human immunodeficiency virus antibody
Wang et al. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex
ATE135743T1 (en) MONOCLONAL HUMAN ANTIBODIES AGAINST HIV-I
Cotropia et al. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
EP1016671A3 (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
Fujita et al. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif
Corbeau et al. An early postinfection signal mediated by monoclonal anti-beta 2 microglobulin antibody is responsible for delayed production of human immunodeficiency virus type 1 in peripheral blood mononuclear cells
Pal et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A
EP0725654A1 (en) Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
Chen et al. HIV-1 gp41 enhances major histocompatibility complex class I and ICAM-1 expression on H9 and U937 cells
Shieh The role of natural killer cells in simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) infection
WO1995024215A1 (en) Retroviral vaccines, vaccination and immune-therapy for retroviral infections
Morizono et al. Human immunodeficiency virus type 1 (HIV-1) infection and transcytosis activity of a HIV-1 susceptible clone from HeLa cell
EP0491888A4 (en) Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197024.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 53/97 UNDER INID (30) "PRIORITY DATA", REPLACE "NOT FURNISHED" BY "08/867149"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/009686

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2256306

Country of ref document: CA

Ref document number: 2256306

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997926870

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997926870

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997926870

Country of ref document: EP